^
    Apply
    A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (NuTide:302) (NCT03428958)
    Phase 1/2
    NuCana plc
    Completed
    Last update posted :
    04/03/2024
    Initiation :
    10/16/2018
    Primary completion :
    03/19/2024
    Completion :
    03/21/2024
    KRAS • BRAF
    |
    BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium
    A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (NCT05678257)
    Phase 2
    NuCana plc
    Active, not recruiting
    Last update posted :
    04/03/2024
    Initiation :
    04/18/2023
    Primary completion :
    09/01/2024
    Completion :
    03/01/2025
    KRAS • BRAF • UGT1A1
    |
    KRAS wild-type • RAS wild-type • UGT1A1*1*1
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium
    NUC-3373 in Advanced Solid Tumours (NuTide:301) (NCT02723240)
    Phase 1
    University of Oxford
    Completed
    Last update posted :
    02/14/2024
    Initiation :
    01/01/2016
    Primary completion :
    02/24/2020
    Completion :
    02/24/2021
    KRAS • BRAF • VEGFA
    |
    KRAS mutation • BRAF mutation
    |
    fosifloxuridine nafalbenamide (NUC-3373)
    NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours (NCT05714553)
    Phase 1/2
    NuCana plc
    Recruiting
    Last update posted :
    06/23/2023
    Initiation :
    03/08/2023
    Primary completion :
    08/01/2024
    Completion :
    01/01/2025
    MSI
    |
    Keytruda (pembrolizumab) • docetaxel • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium